Article

Effects of early steroid withdrawal after heart transplantation

Duke University, Durham, North Carolina, United States
The Annals of thoracic surgery (Impact Factor: 3.65). 09/2006; 82(2):637-44; discussion 644. DOI: 10.1016/j.athoracsur.2006.03.067
Source: PubMed

ABSTRACT Managing immunosuppression is a significant aspect of posttransplantation patient care. Previously, our institution reported that prednisone could be withdrawn in cardiac allograft recipients without jeopardizing midterm survival. We returned to this group of patients to investigate the long-term effects of our steroid taper protocol.
We reviewed the records of 162 consecutive cardiac transplant recipients from our institution. Patients who underwent transplantation between 1988 and 1990 were treated with traditional triple-therapy immunosuppression (cyclosporine, azathioprine, and prednisone). Beginning June 1990, we instituted a protocol of early steroid taper with discontinuation by 6 months after transplant. The two groups were comparable with respect to age, sex, ethnicity, cause of heart failure, ischemic time, body mass index, and creatinine at the time of transplantation.
Fifty-seven percent of the patients in the early steroid taper group were successfully withdrawn from steroids at 6 months after transplantation. This group had a decreased freedom from and increased frequency of acute rejection (p < 0.01 for each) when compared with the traditional therapy group. There was, however, no difference in freedom from posttransplant coronary artery disease (p = 0.53). The early steroid taper group enjoyed an increased freedom from malignancy (p = 0.01) and trended toward a decreased frequency of infection (p = 0.10) and improved survival (p = 0.06).
Steroid withdrawal is possible in 57% of patients at 6 months after transplantation. The institution of an early steroid taper protocol improves the overall freedom from malignancies and may decrease the frequency of infection and prolong overall survival without increasing the risk of posttransplant coronary artery disease.

0 Followers
 · 
132 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Corticosteroids (CSs) are still the mainstay of induction, rescue and maintenance in heart transplantation (HTx). However, their use is associated with significant and well documented side-effects usually related to the dose administered and the duration of therapy. Moreover CSs interfere with the recipient's quality of life and with the active process of graft tolerance. Physicians have been exploring ways to avoid or reduce CSs in association with other immunosuppressive drugs, minimizing side-effects and costs. The regimens are classified as steroid-free or steroid withdrawal protocols. The studies analyzed in this review come to similar conclusions as benefits and adverse consequences: steroid-free protocols should be advisable and mandatory in pediatric patients, insulin-dependent diabetes mellitus (IDDM), presence of infection, familial metabolic disorders/obesity, severe osteoporosis and in the elderly. On the other hand, steroid withdrawal can be successfully achieved in 50-80%, with late better than early withdrawal, no increase in rejection-related mortality, no adverse impact on survival and probably a better quality of live. Safety and efficacy can certainly be improved by an individualized approach to the transplant recipient. This article is protected by copyright. All rights reserved.
    Transplant International 03/2014; 27(6). DOI:10.1111/tri.12309 · 3.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to investigate ocular manifestations of patients undergoing heart transplantations. We retrospectively reviewed the clinical data of 311 patients who underwent orthotropic heart transplantations from January 1989 to December 2007, including the demographic data, general conditions, medications, as well as the basic ophthalmic examinations, ophthalmic diagnosis, and management. Of the 311 heart transplant recipients, common diagnoses included cataract (96 cases; 30.87%), dry eye syndrome (24 cases; 7.72%), allergic conjunctivitis (78 cases; 25.08%), and glaucoma (19 cases; 6.11%). The patients after heart transplantation had much lower incidences of severe opportunistic infections than patients undergoing the same procedure one decade ago. However, autoimmune-related endocrinopathy such as diabetes and Graves' disease became more prevalent. Diabetes-related complications were unexpectedly frequent, including nonproliferative diabetic retinopathy (6 cases; 1.93%), proliferative diabetic retinopathy (6 cases; 1.93%), retinal vein occlusion (6 cases; 1.93%), and neovascular glaucoma (4 cases; 1.29%). The occurrence of cataract formation and steroid glaucoma was often due to post-transplantation steroid use. Ophthalmologists and cardiac surgeons should collaborate and perform regular ophthalmic examinations, especially for those who have new-onset diabetes and difficulty tapering off steroids.
    Transplantation Proceedings 04/2014; 46(3):937-40. DOI:10.1016/j.transproceed.2013.11.149 · 0.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: -A noninvasive biomarker which could accurately diagnose acute rejection (AR) in heart transplant recipients could obviate the need for surveillance endomyocardial biopsies (EMB). We assessed the performance metrics of a novel highly sensitive (hs) cardiac troponin I (cTnI) assay for this purpose. -Stored serum samples were retrospectively matched to EMB in 98 cardiac transplant recipients who survived ≥ 3 months post-transplant. AR was defined as ISHLT grade 2R or higher cellular rejection, acellular rejection, or allograft dysfunction of uncertain etiology leading to treatment for presumed rejection. cTnI was measured with a hs assay (Abbott Diagnostics). Cross-sectional analyses determined the association of cTnI concentrations with rejection and ISHLT grade; and the performance metrics of cTnI for the detection of AR. Among 98 subjects, 37% had at least one rejection episode. cTnI was measured in 418 serum samples, including 35 paired to a rejection episode. cTnI concentrations were significantly higher in rejection versus nonrejection samples (median 57.1 vs. 10.2 ng/L, p < 0.0001), and increased in a graded manner with higher biopsy scores (ptrend < 0.0001). The c-statistic to discriminate AR was 0.82 (95% CI 0.76-0.88). Using a cut-point of 15 ng/L, sensitivity was 94%, specificity 60%, positive predictive value 18%, and negative predictive value 99%. -A hs-cTnI assay appears useful to "rule out" AR in cardiac transplant recipients. If validated in prospective studies, a strategy of serial monitoring with a hs-cTnI assay may offer a low-cost noninvasive strategy for rejection surveillance.
    Circulation Heart Failure 04/2014; 7(3). DOI:10.1161/CIRCHEARTFAILURE.113.000697 · 5.95 Impact Factor

Preview

Download
0 Downloads